Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Fineline Cube Apr 21, 2026
Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Fineline Cube Apr 21, 2026
Company Deals

Henlius Biotech Partners with Shantou Central Hospital for Clinical Study Collaboration

Fineline Cube Nov 24, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced a strategic clinical study cooperation agreement with...

Company Medical Device

AnchorDx Initiates US Registrational Study for UriFind Urothelial Carcinoma Diagnostic

Fineline Cube Nov 24, 2022

China-based AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has announced the initiation...

Company R&D

Biocytogen Announces Successful Development of Fully-Human Nano Antibody RenNano

Fineline Cube Nov 24, 2022

Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano...

Company Drug

Kanghong Pharma Receives FDA Approval for KH631 Gene Therapy Trial

Fineline Cube Nov 24, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approval...

Company Deals

Saint Medical Raises Pre-Series B Funding for Structural Heart Disease Solutions

Fineline Cube Nov 24, 2022

Saint Medical Technology, a Nanjing-based medical device maker specializing in valvular disease solutions, has reportedly...

Company Drug

Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study

Fineline Cube Nov 24, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug...

Company Drug

Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer

Fineline Cube Nov 24, 2022

China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...

Company Drug

Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug

Fineline Cube Nov 24, 2022

China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...

Company Drug

Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne

Fineline Cube Nov 24, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical...

Company Drug Legal / IP

FibroGen Sues Former Employees and Two Pharma Firms for Trade Secret Theft

Fineline Cube Nov 23, 2022

US-based FibroGen Inc. has filed a lawsuit against two former employees, Liu Dong and Deng...

Company Deals

JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston

Fineline Cube Nov 23, 2022

Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to...

Company Deals

Jianke.com Files for Hong Kong IPO with Focus on Chronic Disease Management

Fineline Cube Nov 23, 2022

China-based smart healthcare service platform Jianke.com (Fangzhou Inc.) has filed for an initial public offering...

Company Drug

China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study

Fineline Cube Nov 23, 2022

RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co.,...

Policy / Regulatory

Shanghai Hosts Yangtze River Delta Alliance VBP Tender for 44 Drugs

Fineline Cube Nov 23, 2022

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a document indicating that the city will...

Company Drug

BeiGene to Present Final PFS Results for Brukinsa at ASH Meeting

Fineline Cube Nov 23, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced plans to present...

Company Deals

Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening

Fineline Cube Nov 23, 2022

Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a...

Company Deals Medical Device

Endoso Life Raises Pre-Series A Funding for High-End Medical Endoscope Development

Fineline Cube Nov 23, 2022

Endoso Life, a Hangzhou-based developer of high-end medical endoscope systems and devices, has reportedly raised...

Company Drug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

Fineline Cube Nov 23, 2022

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA

Fineline Cube Nov 23, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...

Company Drug

InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore

Fineline Cube Nov 23, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...

Posts pagination

1 … 584 585 586 … 654

Recent updates

  • Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026
  • Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers
  • LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.